NCT01193049 A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175) Status COMPLETED Phase PHASE1
NCT01192360 Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease Status COMPLETED Phase PHASE3
NCT01191424 A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients. Status COMPLETED Phase PHASE2
NCT01190826 Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma Status COMPLETED Phase PHASE2
NCT01189396 Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 Status COMPLETED Phase PHASE2
NCT01188577 Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics Status COMPLETED Phase PHASE1/PHASE2
NCT01187147 Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma Status COMPLETED Phase NA
NCT01185275 A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study) Status COMPLETED Phase N/A
NCT01181895 Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma Status COMPLETED Phase PHASE3
NCT01181063 Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers Status COMPLETED Phase PHASE1
NCT01176747 Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients Status COMPLETED Phase PHASE1/PHASE2
NCT01175434 School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence Status COMPLETED Phase NA
NCT01175174 Clinical, Airway Inflammatory, and HRA Phenotypes, in Preschool Children With Acute Asthmatic Attack Presenting to the ED. Status COMPLETED Phase N/A
NCT01172821 Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II Status COMPLETED Phase PHASE3
NCT01172808 Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I Status COMPLETED Phase PHASE3